Transcatheter Heart Valve Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Transcatheter Aortic Valve Replacement, Trans Catheter Mitral Valve Repair), By Surgical Procedure Type (Transfemoral Approach, Transapical Approach, Transaortic Approach), By End-user (Hospitals, Ambulatory Surgical Centres, Cardiac Catheterization Laboratory) and Region

Transcatheter Heart Valve Market size was valued at US$ 6.33 billion in 2023, projected to grow at a CAGR of 15%  from 2024-2030. Transcatheter heart valves (THV) are used to replace the heart valves with a prosthetic valve for treatment of severe aortic stenosis and mitral regurgitation. These heart valve diseases can be congenital or acquired later in life due to age related life style changes and may be other underlying diseases. If these are not treated can cause heart failure, stroke, blood clots, or death due to sudden cardiac arrest.

Aortic stenosis is a condition when the aortic valve does not fully open, causing blood flow to be restricted. These high-risk patients are those who are ineligible for surgical aortic valve replacement (SAVR) and cannot be operated on. Transcatheter aortic valve replacement (TAVR) includes implanting new aortic valves to restore the aortic valve's capacity to circulate blood. Aortic stenosis is becoming more common, which has led to an increase in the requirement for transcatheter aortic valve implantation.

Key Developments:

• On March 27, 2024: Medtronic plc , a global leader in healthcare technology, announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.
• On Jan 17, 2023: Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Navitor TAVI system is the latest addition to the company's comprehensive transcatheter structural heart portfolio that offers less invasive treatment options to physicians and patients for some of the most common and serious heart diseases.